J Rheumatol 2017 Oct 1. Epub 2017 Oct 1.
From Corrona LLC, Southborough; Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts; Amgen Inc., Thousand Oaks, California; Wade Outcomes Research and Consulting, Salt Lake City, Utah; New York University School of Medicine, New York, New York; Department of Epidemiology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. Sponsored by Corrona LLC. Corrona LLC has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, BMS, Crescendo, Eli Lilly and Company, Genentech, GSK, Horizon Pharma USA, Janssen, Momenta Pharmaceuticals, Novartis, Pfizer, Roche, and UCB. LRH is an employee and shareholder of Corrona LLC, and has a research grant to the University of Massachusetts Medical School from Pfizer. BSS, DHC, and AM are employees and shareholders of Amgen Inc. SR and WM are employees of Corrona LLC. SWW is a consultant of Amgen Inc. JDG is an employee and shareholder of Corrona LLC, and a consultant of Eli Lilly, Genentech, Janssen, Novartis, and Pfizer. CJE is an employee of Corrona LLC and an advisory board member for Merck. L.R. Harrold, MD, MPH, Corrona LLC, and Department of Medicine, University of Massachusetts Medical School; B.S. Stolshek, PharmD, Amgen Inc.; S. Rebello, MPH, Corrona LLC; D.H. Collier, MD, Amgen Inc.; A. Mutebi, PhD, Amgen Inc.; S.W. Wade, MPH, Wade Outcomes Research and Consulting; W. Malley, MS, Corrona LLC, and New York University School of Medicine; J.D. Greenberg, MD, MPH, Corrona LLC; C.J. Etzel, PhD, Corrona LLC, and Department of Epidemiology, University of Texas, MD Anderson Cancer Center. Address correspondence to Dr. L.R. Harrold, University of Massachusetts Medical School, Medicine, 55 Lake Ave. North, Worcester, Massachusetts 01655, USA. E-mail: Accepted for publication July 19, 2017.
: Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA).Methods
: Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation.Results
: Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8. Read More